Alkermes PLC (FRA:8AK) Stock Price, Trades & News

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.32
Equity-to-Asset	0.41
Debt-to-Equity	0.9
Debt-to-EBITDA	5.72
Interest Coverage	5.79
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.6	Distress Grey Safe
Beneish M-Score	-1.4	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.8
	3-Year EBITDA Growth Rate	75.1
	3-Year EPS without NRI Growth Rate	61.4
	3-Year Book Growth Rate	20
	Future 3-5Y Total Revenue Growth Rate Estimate	11.02

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	49.83
	9-Day RSI	55.22
	14-Day RSI	60.2
	3-1 Month Momentum %	32.52
	6-1 Month Momentum %	41.24
	12-1 Month Momentum %	51.49

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.27
	Quick Ratio	1.7
	Cash Ratio	0.85
	Days Inventory	384.4
	Days Sales Outstanding	79.63
	Days Payable	152.88

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.2
	Shareholder Yield %	-2.28

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	86.63
	Operating Margin %	12.28
	Net Margin %	9.78
	EBITDA Margin %	17.69
	FCF Margin %	14.09
	OCF Margin %	16.29
	ROE %	9.05
	ROA %	5.69
	ROIC %	10.12
	3-Year ROIIC %	44.94
	ROC (Joel Greenblatt) %	39.33
	ROCE %	10.94
	Years of Profitability over Past 10-Year	3
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	58.58
	Forward PE Ratio	21.6
	PE Ratio without NRI	58.58
	Price-to-Owner-Earnings	99.28
	PS Ratio	5.67
	PB Ratio	5.01
	Price-to-Free-Cash-Flow	40.65
	Price-to-Operating-Cash-Flow	35.12
	EV-to-EBIT	41.55
	EV-to-Forward-EBIT	12.49
	EV-to-EBITDA	35.66
	EV-to-Forward-EBITDA	11.47
	EV-to-Revenue	6.31
	EV-to-Forward-Revenue	5.43
	EV-to-FCF	44.44
	Price-to-GF-Value	1.94
	Price-to-Projected-FCF	2.62
	Price-to-Median-PS-Value	1.65
	Price-to-Peter-Lynch-Fair-Value	2.34
	Earnings Yield (Greenblatt) %	2.41
	FCF Yield %	2.52
	Forward Rate of Return (Yacktman) %	22.4

Financials (Next Earnings Date:2026-07-28)

Annual Quarterly TTM

FRA:8AK's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Alkermes PLC Executives

Details

GF Value™: €23.51

FRA:8AK

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 8AK. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	1,342.817
	EPS (TTM) (€)	0.77
	Beta	0.926
	3-Year Sharpe Ratio	0.59
	3-Year Sortino Ratio	1.12
	Volatility %	47.21
	14-Day RSI	60.2
	14-Day ATR (€)	0.882403
	20-Day SMA (€)	45.268
	12-1 Month Momentum %	51.49
	52-Week Range (€)	22 - 48.19
	Shares Outstanding (Mil)	166.68

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Alkermes PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Alkermes PLC Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-28 08:00	In 102 days
Third quarter earnings results for 2026	2026-10-28	In 101 days
Second quarter earnings conference call for 2026	2026-07-28 08:00	In 10 days
Second quarter earnings results for 2026	2026-07-28	In 9 days
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-10 10:00	37.28 (+2.36%)
General meeting for 2026	2026-05-20 14:00	31.60 (+0.00%)
First quarter earnings conference call for 2026	2026-05-05 08:00	28.11 (+0.00%)
First quarter earnings results for 2026	2026-05-05	28.11 (+0.00%)
Guidance call for 2026	2026-03-17 08:30	24.00 (+0.00%)
the TD Cowen 46 Annual Health Care Conference	2026-03-02 09:10	25.40 (+0.00%)

Show

Entries

Alkermes PLC Frequently Asked Questions

What is Alkermes PLC(FRA:8AK)'s stock price today?

The current price of FRA:8AK is €45.50. The 52 week high of FRA:8AK is €48.19 and 52 week low is €22.00.

When is next earnings date of Alkermes PLC(FRA:8AK)?

The next earnings date of Alkermes PLC(FRA:8AK) is 2026-07-28.

Does Alkermes PLC(FRA:8AK) pay dividends? If so, how much?

Alkermes PLC(FRA:8AK) does not pay dividend.

Press Release

	Subject	Date
	Alkermes to Report Second Quarter Financial Results on July 28, 2026	2026-07-14
	Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis	2026-07-13
	Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026	2026-06-17
	Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe	2026-06-15
	Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research	2026-06-04
	Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-03
	Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting	2026-05-26
	Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences	2026-05-21
	Alkermes to Report First Quarter Financial Results on May 5, 2026	2026-04-21
	Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting	2026-04-16

10/Page

Articles on Alkermes PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.